Literature DB >> 22231292

Prostate cancer: cardiovascular risk and androgen deprivation therapy.

Mina Razzak.   

Abstract

Entities:  

Year:  2012        PMID： 22231292     DOI： 10.1038/nrurol.2011.229

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Authors:  Paul L Nguyen; Youjin Je; Fabio A B Schutz; Karen E Hoffman; Jim C Hu; Arti Parekh; Joshua A Beckman; Toni K Choueiri
Journal:  JAMA       Date:  2011-12-07       Impact factor: 56.272

2.  Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

Authors:  Laurent Azoulay; Hui Yin; Serge Benayoun; Christel Renoux; Jean-François Boivin; Samy Suissa
Journal:  Eur Urol       Date:  2011-08-27       Impact factor: 20.096
  2 in total
  3 in total

Review 1.  Androgen receptor (AR) in cardiovascular diseases.

Authors:  Chiung-Kuei Huang; Soo Ok Lee; Eugene Chang; Haiyan Pang; Chawnshang Chang
Journal:  J Endocrinol       Date:  2016-01-14       Impact factor: 4.286

2.  The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.

Authors:  D J P Henderson; A Byrne; K Dulla; G Jenster; R Hoffmann; G S Baillie; M D Houslay
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

3.  Assessment of androgen receptor, IGF-IR and insulin receptor expression in male patients with severe peripheral artery disease.

Authors:  Michele Andreucci; Damiano Cosimo Rigiracciolo; Umberto Marcello Bracale; Nicola Ielapi; Michele Provenzano; Diletta D'Iuorno; Ashour Michael; Pasquale Mastroroberto; Giuseppe Filiberto Serraino; Marcello Maggiolini; Raffaele Serra
Journal:  Heliyon       Date:  2022-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.